Trending...
- STRETCHIT Announces it is Now Available to Millions of Employees on Wellhub, the Leader in Corporate Wellness
- Arthur Murray Dance Studio Modena: Discover the Joy of Dance
- C-Data Unveils Next-Gen Distributed PON Solution, Redefining PON Architecture
PITTSBURGH, Aug. 27, 2024 ~ MolecuLight Corp., a renowned company in the field of fluorescence imaging technology, has recently announced a major development in their flagship wound imaging device, MolecuLightDX. The company has successfully integrated this device with the Intellicure EHR platform, a leading electronic health record system.
This integration allows wound care clinicians who use Intellicure's SMART apps or its complete EHR solution to seamlessly upload standard and fluorescence images and measurements captured with the MolecuLight device at the point-of-care directly to the patient's record. This not only optimizes their workflow but also enables them to digitally document their patients' wounds.
The benefits of this integration are numerous, including direct (Wi-fi enabled) EHR-to-device transfer of patient data, automatic upload of images from device-to-EHR, digital wound measurement and standard wound images, as well as bacterial autofluorescence images that indicate the presence and location of harmful bacteria and biofilm in and around wounds. Additionally, this integration is scalable and supports the use of several DX devices per site.
More on The PennZone
Anil Amlani, CEO of MolecuLight Inc., expressed his excitement about this development by stating that "optimizing our customers' clinical workflow is a top priority here at MolecuLight." He further added that "we are proud to announce the inclusion of our MolecuLight platform in Intellicure EHR." Amlani also highlighted the advanced features of MolecuLightDX, which is an extensively validated FDA-cleared Class II device that integrates three essential functions: detection of harmful bacteria linked to infection, digital wound measurement, and aid to clinicians in treatment planning. He also mentioned that an extensive body of peer-reviewed publications demonstrates faster healing rates, better resource allocation, cost savings, and improved patient engagement with the use of their advanced imaging platform.
Dr. Caroline Fife, Chief Medical Officer at Intellicure, also expressed her enthusiasm about this integration by stating that "Intellicure's seamless wound care charting platform is a perfect match with MolecuLight." She further added that "Intellicure is the only wound care EHR that provides relevant point-of-care clinical practice suggestions." Dr. Fife also highlighted the importance of this integration in optimizing patient care and improving wound outcomes.
More on The PennZone
The MolecuLight i:X and DX are the only Class ll FDA-cleared, CE-Marked, and Health Canada approved imaging devices available in the market for the real-time detection of elevated bacterial burden in and around wounds. With a robust body of clinical evidence, these devices are used globally by leading wound care facilities.
On the other hand, Intellicure is a wound care software used by America's advanced wound centers. Wound clinicians using Intellicure's SMART apps for Cerner and Epic, wound care mobile apps, and/or Intellicure's complete EHR solution enjoy clean clinical workflow, proven regulatory compliance, unparalleled reimbursement rates, and are recognized by CMS as leaders in quality patient care. This integration with MolecuLight further strengthens their position as a leader in the field of wound care.
Overall, this integration between MolecuLightDX and Intellicure EHR is a significant development that will greatly benefit both clinicians and patients. It not only streamlines their workflow but also provides valuable information about harmful bacteria to aid in treatment planning and ultimately improve patient outcomes.
This integration allows wound care clinicians who use Intellicure's SMART apps or its complete EHR solution to seamlessly upload standard and fluorescence images and measurements captured with the MolecuLight device at the point-of-care directly to the patient's record. This not only optimizes their workflow but also enables them to digitally document their patients' wounds.
The benefits of this integration are numerous, including direct (Wi-fi enabled) EHR-to-device transfer of patient data, automatic upload of images from device-to-EHR, digital wound measurement and standard wound images, as well as bacterial autofluorescence images that indicate the presence and location of harmful bacteria and biofilm in and around wounds. Additionally, this integration is scalable and supports the use of several DX devices per site.
More on The PennZone
- America Is Being Ripped Off: It's Time To Take Action Against Fraud & Foreign Exploitation
- Independence Title Honored for Excellence in Fraud Prevention by Stewart Title
- Dentaluxe's New Website Launch!
- PawTides.com Partners with Rescue 22 Foundation to Support Veterans and Rescue Dogs
- Pan-Armenian Digital Trade Center Launched on Fastexverse
Anil Amlani, CEO of MolecuLight Inc., expressed his excitement about this development by stating that "optimizing our customers' clinical workflow is a top priority here at MolecuLight." He further added that "we are proud to announce the inclusion of our MolecuLight platform in Intellicure EHR." Amlani also highlighted the advanced features of MolecuLightDX, which is an extensively validated FDA-cleared Class II device that integrates three essential functions: detection of harmful bacteria linked to infection, digital wound measurement, and aid to clinicians in treatment planning. He also mentioned that an extensive body of peer-reviewed publications demonstrates faster healing rates, better resource allocation, cost savings, and improved patient engagement with the use of their advanced imaging platform.
Dr. Caroline Fife, Chief Medical Officer at Intellicure, also expressed her enthusiasm about this integration by stating that "Intellicure's seamless wound care charting platform is a perfect match with MolecuLight." She further added that "Intellicure is the only wound care EHR that provides relevant point-of-care clinical practice suggestions." Dr. Fife also highlighted the importance of this integration in optimizing patient care and improving wound outcomes.
More on The PennZone
- Express Wash Concepts Announces Pittsburgh Expansion with Grand Opening of 11th Clean Express Auto Wash
- U.S. Army Selects Nokomis to Develop Passive Drone Detection, Tracking, and Identification System
- Stern Recruiting Launches with a Mission to Revolutionize Talent Acquisition
- Bonita Mitchell Releases Inspiring Single "Let This Mind Be In Me" From Book Soundtrack 'The First Lady'
- Webinar Announcement: Collaborating for Digital Transformation: Innovation, Governance, and the Future of Financial Operations
The MolecuLight i:X and DX are the only Class ll FDA-cleared, CE-Marked, and Health Canada approved imaging devices available in the market for the real-time detection of elevated bacterial burden in and around wounds. With a robust body of clinical evidence, these devices are used globally by leading wound care facilities.
On the other hand, Intellicure is a wound care software used by America's advanced wound centers. Wound clinicians using Intellicure's SMART apps for Cerner and Epic, wound care mobile apps, and/or Intellicure's complete EHR solution enjoy clean clinical workflow, proven regulatory compliance, unparalleled reimbursement rates, and are recognized by CMS as leaders in quality patient care. This integration with MolecuLight further strengthens their position as a leader in the field of wound care.
Overall, this integration between MolecuLightDX and Intellicure EHR is a significant development that will greatly benefit both clinicians and patients. It not only streamlines their workflow but also provides valuable information about harmful bacteria to aid in treatment planning and ultimately improve patient outcomes.
Filed Under: Business
0 Comments
Latest on The PennZone
- Unveil Hydrogen-Powered Maritime Innovation at H2Hub Summit
- Brookline Family Dentistry Updates Website URL for a Stronger Brand Identity
- Major Defense Contractor, Satellite and Multiple Deployable Tech Companies Partnering with Ascent Solar Technologies, Inc: Stock Symbol: ASTI
- Rosann Santos Ofrece el Programa Repensando el Síndrome del Impostor™
- Criptlán Partners with Top Capital and Technology Teams to Drive the Future of the Digital Economy
- From Sea to the Site: The Evolution of the Shipping Container From the Water to the Worksite
- JKS Financial Sponsors Rebound Rewards with University of Pittsburgh Men's Basketball
- QVC Group Appoints Alex Wellen as President & Chief Growth Officer
- Inbound Lead Generation for Security Companies in 2025: The Key to Sustainable Growth
- Frame Up Now Leverages Cyntexa and Salesforce to Fuel Their Operations & Power Up Lead Conversion
- M Film Lab Launches Spring 2025 Screenwriting Lab: Tales of Identity & Imagination
- Pittsburgh Upcoming Wedding Videographer
- TFL Tech Inc. Launches New & Improved Website
- The Right Reverend Mariann Edgar Budde, Bishop of the Episcopal Diocese of Washington, Joins Seabury Resources for Aging® Board of Governors
- Aries Industries Celebrates 40 Years of Innovation, Growth and Service
- Royalty Settlement in Patent Infringement Suit with New Strategic Partnership for AI Marketing Tech Company: Alpha Modus Corp. (Stock Symbol:: AMOD)
- $300 Million in Milestones Plus Tiered Double-Digit Royalties to License & Distribute NRX-100 Drug: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
- C-Data Unveils Next-Gen Distributed PON Solution, Redefining PON Architecture
- Mental Health Watchdog Seeks Action Amid Alarming Patient Sexual Abuse Cases
- RECOVERY CENTERS OF AMERICA AND PHILADELPHIA EAGLES LAUNCH LIFE-SAVING ADDICTION TREATMENT INITIATIVE